Literature DB >> 27653560

T1 hyperintensity on brain imaging subsequent to gadolinium-based contrast agent administration: what do we know about intracranial gadolinium deposition?

Nigel Hoggard1, Giles H Roditi2.   

Abstract

There is growing evidence for the accumulation of gadolinium (Gd) in patients administered with intravenous Gd-based contrast agents, even in the absence of renal impairment. This review of the literature will discuss what has been found to date in cadaveric human studies, clinical studies of patients and from animal models. Evidence for the potential route of entry into the brain will be examined. The current state of knowledge of effects of Gd accumulation in the brain is discussed. We will then discuss what the possible implications may be for the choice of Gd-based contrast agents in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27653560      PMCID: PMC5605029          DOI: 10.1259/bjr.20160590

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  46 in total

1.  Gadolinium encephalopathy due to accidental intrathecal administration of gadopentetate dimeglumine.

Authors:  Sönke Arlt; Lukas Cepek; Hans Heino Rustenbeck; Hilmar Prange; Carl Detlev Reimers
Journal:  J Neurol       Date:  2007-04-02       Impact factor: 4.849

2.  Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?

Authors:  Thomas Grobner
Journal:  Nephrol Dial Transplant       Date:  2006-01-23       Impact factor: 5.992

Review 3.  Manganese accumulation in the brain: MR imaging.

Authors:  A Uchino; T Noguchi; K Nomiyama; Y Takase; T Nakazono; J Nojiri; S Kudo
Journal:  Neuroradiology       Date:  2007-07-12       Impact factor: 2.804

4.  Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy.

Authors:  Shawn E Cowper
Journal:  Am J Kidney Dis       Date:  2005-10       Impact factor: 8.860

5.  Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging.

Authors:  Peter Marckmann; Lone Skov; Kristian Rossen; Anders Dupont; Mette Brimnes Damholt; James Goya Heaf; Henrik S Thomsen
Journal:  J Am Soc Nephrol       Date:  2006-08-02       Impact factor: 10.121

6.  Gadolinium encephalopathy in a patient with renal failure.

Authors:  Boby Varkey Maramattom; Edward M Manno; Eelco F M Wijdicks; Edward P Lindell
Journal:  Neurology       Date:  2005-04-12       Impact factor: 9.910

7.  Scleromyxoedema-like cutaneous diseases in renal-dialysis patients.

Authors:  S E Cowper; H S Robin; S M Steinberg; L D Su; S Gupta; P E LeBoit
Journal:  Lancet       Date:  2000-09-16       Impact factor: 79.321

8.  Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy.

Authors:  Gregory W White; Wendell A Gibby; Michael F Tweedle
Journal:  Invest Radiol       Date:  2006-03       Impact factor: 6.016

9.  Neurotoxicological consequence of long-term exposure to lanthanum.

Authors:  Liuxing Feng; Haiqing Xiao; Xiao He; Zijie Li; Fuliang Li; Nianqing Liu; Yuliang Zhao; Yuying Huang; Zhiyong Zhang; Zhifang Chai
Journal:  Toxicol Lett       Date:  2006-03-06       Impact factor: 4.372

10.  Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort.

Authors:  Tara Anne Collidge; Peter Campbell Thomson; Patrick Barry Mark; James Phillip Traynor; Alan George Jardine; Scott Thomas William Morris; Keith Simpson; Giles Hannibal Roditi
Journal:  Radiology       Date:  2007-08-17       Impact factor: 11.105

View more
  4 in total

1.  T1 Signal Measurements in Pediatric Brain: Findings after Multiple Exposures to Gadobenate Dimeglumine for Imaging of Nonneurologic Disease.

Authors:  G K Schneider; J Stroeder; G Roditi; C Colosimo; P Armstrong; M Martucci; A Buecker; P Raczeck
Journal:  AJNR Am J Neuroradiol       Date:  2017-06-22       Impact factor: 3.825

2.  Central nervous system gadolinium accumulation in patients undergoing periodical contrast MRI screening for hereditary tumor syndromes.

Authors:  Evelynn Vergauwen; Anne-Marie Vanbinst; Carola Brussaard; Peter Janssens; Dieter De Clerck; Michel Van Lint; Anne C Houtman; Olaf Michel; Kathelijn Keymolen; Bieke Lefevere; Susanne Bohler; Dirk Michielsen; Anna C Jansen; Vera Van Velthoven; Sven Gläsker
Journal:  Hered Cancer Clin Pract       Date:  2018-01-05       Impact factor: 2.857

Review 3.  Gadolinium: pharmacokinetics and toxicity in humans and laboratory animals following contrast agent administration.

Authors:  Julie Davies; Petra Siebenhandl-Wolff; Francois Tranquart; Paul Jones; Paul Evans
Journal:  Arch Toxicol       Date:  2022-01-08       Impact factor: 5.153

4.  High-resolution Imaging of Myeloperoxidase Activity Sensors in Human Cerebrovascular Disease.

Authors:  Youssef Z Wadghiri; Dung Minh Hoang; Anita Leporati; Matthew J Gounis; Aurora Rodríguez-Rodríguez; Mary L Mazzanti; John P Weaver; Ajay K Wakhloo; Peter Caravan; Alexei A Bogdanov
Journal:  Sci Rep       Date:  2018-05-16       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.